AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

NEXT STORY
MATEON PARTNERED WITH CHOPRA FOUNDATION ON ARTIVEDA™
PREV STORY
Front Line Medical Technologies Receives Health Canada Approval for Groundbreaking Medical Device to Control Bleeding and Help Patients Survive Emergency Situations
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Actinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical Officer

Dr. Berger brings 20 years of drug development experience highlighted by the FDA approvals ...

author_avatar
NASDAQ Market News

The Global Biosimilars Market is expected to grow by $ 31.40 bn during 2021-2025, progressing at a CAGR of 24.77% during the forecast period

author_avatar
NASDAQ Market News

Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer

author_avatar
NASDAQ Market News